Plenary Session 2: Landscape

**Measles Aerosol Vaccine**

**Measles Vaccine, Dry Powder (Inhalable)**

*Next-Generation Vaccine Delivery Technology Meeting*
Geneva, Switzerland

**Name:** Dr. S. S. Jadhav

**Email:** ssj@seruminsitute.com

**Title:** Executive Director SSI

**Date:** February 18, 2014
CAN-BD Spray Drying System

Technology Description:

- Carbon Dioxide Assisted Nebulization with a Bubble Dryer®
Measles Vaccine, Dry Powder (Inhalable)

PuffHaler

Solovent™ devices

ADAPTIVE SPACER DESIGN FOR ADULTS & CHILDREN - CONFIGURED AT TIME OF USE
Measles Vaccine, Dry Powder (Inhalable)

Status:

✓ Validation
✓ Technology transfer
✓ Bench testing
✓ Animal immunogenicity
✓ Animal Toxicity
✓ Phase 1 in healthy adults
Measles Vaccine, Dry Powder (Inhalable)

Benefits:

✓ Non injectable, easier to administer
✓ No waste disposal
✓ Competitive cost per dose

Challenges:

• Need data from Phase II and III clinical trials to further assess immunogenicity and safety
• Resources to complete clinical development
• Sale up of manufacturing
Measles Vaccine, Dry Powder: Opportunities and Way Forward

Global Public Health Challenge:

- Simplify delivery of vaccine
- Reduce safety concerns
- Expand coverage

Technology Availability:

- Probability of technology availability for program use in the next 10 – 20 years if not sooner
- What is needed to realize availability of technology?
- Suggestions for the way forward

http://www.aktiv-dry.com/images/Aktiv_Dry_for_Powerpoint.mov